Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ideaya Biosciences Inc chart...

About the Company

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.

CEO

Yujiro Hata

Exchange

NASDAQ

Website

https://www.ideayabio.com/

$152M

Total Revenue

102

Employees

$3B

Market Capitalization

-26.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $IDYA News

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

28d ago, source: Yahoo Finance

Feb. 20, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a ...

Ideaya Biosciences

14d ago, source: Forbes

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular ...

IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial Cancer

6d ago, source:

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced Tuesday that it has entered into a clinical trial ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results

25d ago, source: Yahoo Finance

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to US$44.55 in the week after its latest full-year results. It looks like ...

IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events

14d ago, source: Nasdaq

SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics ...

IDEAYA Biosciences Stock (NASDAQ:IDYA), Quotes and News Summary

10d ago, source: Benzinga.com

Abri's stockholders approved its proposed business combination with DLQ. Ideaya Biosciences Inc (NASDAQ: IDYA) shares are trading lower by 11.6% to $24.10 Wednesday morning after the company ...

Ideaya Biosciences Inc. Registered Shares DL-,01 Aktie

20d ago, source: Finanzen100

Bitte entschuldigen Sie den Fehler. Sollte dieser Fehler erneut auftreten, kontaktieren Sie bitte unseren Kundeservice per E-Mail.

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

2mon ago, source: Stockhouse

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...

IDEAYA Biosciences Inc.

7d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Ideaya Biosciences Inc (IDYA)

7d ago, source: Investing

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...